Software that measures coronary plaque
On 29 July 2026 the FDA granted De Novo authorisation to the first device that quantifies coronary inflammation from CT. It is the latest step in a shift of the cardiology target from stenosis to the vessel wall, backed by plaque analysis software already reimbursed in the United States. What is validated, what is not, and what is still missing.
Read more